Directly to content
  1. Publishing |
  2. Search |
  3. Browse |
  4. Recent items rss |
  5. Open Access |
  6. Jur. Issues |
  7. DeutschClear Cookie - decide language by browser settings

Association of angiogenic factors with prognosis in esophageal cancer

Dreikhausen, Lena ; Blank, Susanne ; Sisic, Leila ; Heger, Ulrike ; Weichert, Wilko ; Jäger, Dirk ; Bruckner, Thomas ; Giese, Natalia ; Grenacher, Lars ; Falk, Christine ; Ott, Katja ; Schmidt, Thomas

In: BMC cancer, 15 (2015), Nr. 121. pp. 1-11. ISSN 1471-2407

[img]
Preview
PDF, English
Download (675kB) | Lizenz: Creative Commons LizenzvertragAssociation of angiogenic factors with prognosis in esophageal cancer by Dreikhausen, Lena ; Blank, Susanne ; Sisic, Leila ; Heger, Ulrike ; Weichert, Wilko ; Jäger, Dirk ; Bruckner, Thomas ; Giese, Natalia ; Grenacher, Lars ; Falk, Christine ; Ott, Katja ; Schmidt, Thomas underlies the terms of Creative Commons Attribution 3.0 Germany

Citation of documents: Please do not cite the URL that is displayed in your browser location input, instead use the DOI, URN or the persistent URL below, as we can guarantee their long-time accessibility.

Abstract

Background: Despite multimodal therapy esophageal cancer often presents with poor prognosis. To improve outcome, tumor angiogenesis and anti-angiogenic therapeutic agents have recently gained importance. However, patient subgroups who benefit from anti-angiogenic therapy are not yet defined. In this retrospective exploratory study we investigated 9 angiogenic factors in patients’ serum and tissue samples with regard to their association with clinicopathological parameters, prognosis and response in patients with locally advanced preoperatively treated esophageal cancer. Methods: From 2007 to 2012 preoperative serum and corresponding tumor tissue (n = 54), only serum (n = 20) or only tumor tissue (n = 4) were collected from esophageal squamous cell carcinoma (SCC) (n = 34) and adenocarcinoma of the esophagogastric junction (AEG) (n = 44) staged cT3/4NanyM0/x after preoperative chemo(radio)therapy. Angiogenic cytokine levels in both tissue and serum were measured by multiplex immunoassay. Results: Median survival in all patients was 28.49 months. No significant difference was found in survival between SCC and AEG (p = 0.90). 26 patients were histopathological responders. Histopathological response was associated with prognosis (p = 0.05). Angiogenic factors were associated with the following clinicopathological factors: tumor tissue expression of Angiopoietin-2 and Follistatin was higher in SCC compared to AEG (p = 0.022 and p = 0.001). High HGF and Follistatin expression in the tumor tissue was associated with poor prognosis in all patients (p = 0.037 and p = 0.036). No association with prognosis was found in the patients’ serum. Neither patients’ serum nor tumor tissue showed an association between angiogenic factors and response to neoadjuvant therapy. Conclusion: Two angiogenic factors (HGF and Follistatin) in posttherapeutic tumor tissue are associated with prognosis in esophageal cancer patients. Biological differences of AEG and SCC with respect to angiogenesis were evident by the different expression of 2 angiogenic factors. Results are promising and should be pursued prospectively, optimally sequentially pre- and posttherapeutically.

Item Type: Article
Journal or Publication Title: BMC cancer
Volume: 15
Number: 121
Publisher: BioMed Central
Place of Publication: London
Date Deposited: 25 Nov 2015 14:14
Date: 2015
ISSN: 1471-2407
Page Range: pp. 1-11
Faculties / Institutes: Medizinische Fakultät Heidelberg > Chirurgische Universitätsklinik
Medizinische Fakultät Heidelberg > Radiologische Universitätsklinik
Medizinische Fakultät Heidelberg > Institut für Medizinische Biometrie und Informatik
Medizinische Fakultät Heidelberg > Pathologisches Institut
Subjects: 610 Medical sciences Medicine
About | FAQ | Contact | Imprint |
OA-LogoDINI certificate 2013Logo der Open-Archives-Initiative